Clinical Trials

Disclaimer: The information in the links below is not provided by Ambit Biosciences Corporation but by a third party and is not intended to be relied on for investment purposes. Ambit Biosciences Corporation does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.

Quizartinib (AC220)

• A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
  Status: Complete
• Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
  Status: Active, Not Recruiting
• Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
  Status: Active, Not Recruiting
• A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
  Status: Recruiting Patients
• A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
  Status: Recruiting Patients
• A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) 
  Status: Recruiting Patients
• An Open Label Study to Evaluate the Safety and Efficacy of Two Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia 
  Status: Recruiting Patients
• A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220 or the CXCR4 Inhibitor Plerixafor With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)
  Status: Recruiting Patients

AC430/AC410 (JAK2)

• Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
  Status: Complete